Assessment of Fit in Longitudinal Data for Joint Models with Applications to Cancer Clinical Trials
暂无分享,去创建一个
Joseph G. Ibrahim | Ming-Hui Chen | Danjie Zhang | J. Ibrahim | Ming-Hui Chen | W. Shen | M. E. Boye | Wei Shen | Danjie Zhang | M. Boye
[1] Hongtu Zhu,et al. Bayesian Influence Measures for Joint Models for Longitudinal and Survival Data , 2012, Biometrics.
[2] E. Eisenhauer,et al. Progression-free survival: meaningful or simply measurable? , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] Claude Denham,et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] V. DeGruttola,et al. Models for empirical Bayes estimators of longitudinal CD4 counts. , 1996, Statistics in medicine.
[5] Joseph G. Ibrahim,et al. A new joint model for longitudinal and survival data with a cure fraction , 2004 .
[6] Ping Wang,et al. Joint modeling of longitudinal outcomes and survival using latent growth modeling approach in a mesothelioma trial , 2012, Health Services and Outcomes Research Methodology.
[7] V. De Gruttola,et al. Modelling progression of CD4-lymphocyte count and its relationship to survival time. , 1994, Biometrics.
[8] J. Ibrahim,et al. Handbook of survival analysis , 2014 .
[9] Bradley P. Carlin,et al. Multilevel Bayesian Models for Survival Times and Longitudinal Patient-Reported Outcomes With Many Zeros , 2012 .
[10] James J. Rusthoven,et al. Measuring quality of life in patients with pleural mesothelioma using a modified version of the Lung Cancer Symptom Scale (LCSS): psychometric properties of the LCSS-Meso , 2005, Supportive Care in Cancer.
[11] Pennifer Erickson,et al. Use of existing patient-reported outcome (PRO) instruments and their modification: the ISPOR Good Research Practices for Evaluating and Documenting Content Validity for the Use of Existing Instruments and Their Modification PRO Task Force Report. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[12] Joseph G. Ibrahim,et al. Bayesian Survival Analysis , 2004 .
[13] Wei Shen,et al. Assessing model fit in joint models of longitudinal and survival data with applications to cancer clinical trials , 2014, Statistics in medicine.
[14] G. Schwarz. Estimating the Dimension of a Model , 1978 .
[15] Joseph G Ibrahim,et al. Sample size and power determination in joint modeling of longitudinal and survival data , 2011, Statistics in medicine.
[16] H. Akaike,et al. Information Theory and an Extension of the Maximum Likelihood Principle , 1973 .
[17] M. Kris,et al. A dilemma in analysis: issues in the serial measurement of quality of life in patients with advanced lung cancer. , 1997, Lung cancer.
[18] Joseph G Ibrahim,et al. Bayesian Approaches to Joint Cure‐Rate and Longitudinal Models with Applications to Cancer Vaccine Trials , 2003, Biometrics.
[19] J. Ibrahim,et al. A Bayesian semiparametric joint hierarchical model for longitudinal and survival data. , 2003, Biometrics.
[20] Yudi Pawitan,et al. Modeling Disease Marker Processes in AIDS , 1993 .
[21] Joseph G Ibrahim,et al. Basic concepts and methods for joint models of longitudinal and survival data. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] F. Hsieh,et al. Joint Modeling of Survival and Longitudinal Data: Likelihood Approach Revisited , 2006, Biometrics.
[23] Joseph G. Ibrahim,et al. BAYESIAN METHODS FOR JOINT MODELING OF LONGITUDINAL AND SURVIVAL DATA WITH APPLICATIONS TO CANCER VACCINE TRIALS , 2004 .
[24] Bradley P Carlin,et al. Joint Modeling of Multiple Longitudinal Patient-Reported Outcomes and Survival , 2011, Journal of biopharmaceutical statistics.